AB2 Bio Ltd. And others For more information, visit Adult-onset Still Disease Market Analysis, Patient Pool, and Emerging Therapies Scope of the Adult-onset Still Disease Market Report: 11 Years ...

Alerted by our American colleagues, we worked with AB2 Bio Ltd. to determine what dose she should be given. The Food and Drug Administration granted permission to use the drug in a last-ditch attempt ...

AB2 Bio Ltd., a biotechnology company developing innovative therapies for the treatment of severe systemic hyperinflammatory diseases and conditions driven by IL-18, announced today it has entered ...

AB2 Bio has made an option and licencing agreement with Nippon Shinyaku, granting the latter the option to obtain exclusive rights to commercialise Tadekinig alfa in the US. This therapy treats a rare ...

Agreement grants Nippon Shinyaku an option to acquire exclusive U.S. rights to commercialize AB2 Bio’s Tadekinig alfa to treat Primary Monogenic IL-18 driven Hyperinflammatory Syndrome in patients ...

I am delighted to enter into an agreement with AB2 Bio to bring this extremely promising therapy to the U.S. patients that need it.” “As the Chair of AB2 Bio, I am very pleased to welcome our new ...

AB2 Bio retains rights to Tadekinig alfa for all other indications in the U.S. (including Guam, Puerto Rico and U.S. Virgin Islands) and all indications in the rest of the world.

“AB2 Bio is a global pioneer in developing therapies for IL-18 driven diseases and conditions,” said Dr. Toru Nakai, President & Representative Director of Nippon Shinyaku. “Monogenic IL-18 driven ...